Physician profile
Brandon E Locklear
NPI 1740447531
$1,852.18
in general payments reported to CMS, 2019-2025
24 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $48.47 · 2021: $22.47 · 2022: $573 · 2023: $289 · 2024: $137 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $392.22 | 2022 | |
| Ethicon US, LLC | $282.42 | 2019-2024 | Stratafix, Mega Soft, Vistaseal |
| Meditrina | $148.38 | 2025 | |
| Minerva Surgical, INC | $145.13 | 2019 | |
| Astellas Pharma US INC | $140.95 | 2023-2025 | Veozah |
| Abbvie INC. | $113.50 | 2019-2022 | |
| Hologic Sales and Service, LLC | $84.92 | 2019-2024 | Thinprep 2000 Processor, Aptima |
| Organon LLC | $57.58 | 2022-2025 | Nexplanon |
| Coopersurgical, INC. | $51.80 | 2024-2025 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $50.05 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $49.83 | 2025 | |
| Millicent US INC | $44.44 | 2022 | |
| Therapeuticsmd, INC. | $43.81 | 2019 | |
| Agile Therapeutics, INC. | $39.60 | 2022-2023 | Twirla |
| Lupin INC. | $36.63 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $33.95 | 2022-2024 | |
| Vertical Pharmaceuticals, LLC | $23.06 | 2019 | |
| Novo Nordisk INC | $20.57 | 2019 | |
| Myovant Sciences INC. | $19.23 | 2022 | |
| Baxter Healthcare | $19.21 | 2023 | Tisseel |
| Shield Therapeutics INC | $16.24 | 2025 | |
| Allergan, INC. | $12.94 | 2019 | |
| Olympus America INC. | $12.89 | 2023 | Olympus |
| Merck Sharp & Dohme LLC | $12.83 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$159,999.12 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.